PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Signs Distribution Agreement with Canada House Wellness Group

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has signed an agreement with Canada House Wellness Group (CSE: CHV) to distribute concentrate products through existing provincial distribution channels. Canada House Wellness is a fully integrated medical cannabis company. The two companies have entered into a Cannabis 2.0 distribution agreement. The agreement notes that Canada House’s wholly owned subsidiary Abba Medix Corp. will carry and distribute Pure Extracts’ line of concentrate products. Canada House’s leadership team noted that it was impressed with the Pure Extracts team and the brand presence that Pure Extracts has established, specifically in the country’s Western provinces. “This agreement allows us to quickly and efficiently get our outstanding line of full-spectrum oil vape and edible products to retail buyers across Canada while our Sales Amendment application is being processed by Health Canada,” said Pure Extracts CEO Ben Nikolaevsky in the press release.

To view the full press release, visit https://ibn.fm/jcc0t 

About Pure Extracts Technologies Corp.

Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On Sept. 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act. In addition, the company’s stock began trading on the Canadian Securities Exchange (“CSE”) on Nov. 5, 2020. For more information about the company, please visit www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL 

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a…

5 days ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Taps IBN to Lead Corporate Communications Amid Drug Advancements and Subsidiary Launch

NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and…

1 week ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s Priority Voucher for NRX-100 Ketamine Formulation

NRx Pharmaceuticals (NASDAQ: NRXP) has filed for the newly launched FDA Commissioner’s National Priority Voucher…

1 week ago

PsychedelicNewsBreaks – Psyence Biomedical Ltd. (NASDAQ: PBM) to Present at Psychedelic Science 2025

Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its subsidiary HOPE Therapeutics announced a…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics to Present at H.C. Wainwright Neuro Perspectives Conference

NRx Pharmaceuticals (NASDAQ: NRXP) and its wholly owned subsidiary HOPE Therapeutics, Inc. announced participation in…

3 weeks ago